{"id":2092,"date":"2022-09-12T08:32:37","date_gmt":"2022-09-12T08:32:37","guid":{"rendered":"https:\/\/neuropediatoolbox.org\/?p=2092"},"modified":"2026-08-11T10:17:21","modified_gmt":"2026-08-11T10:17:21","slug":"palivizumab-en-ninos-con-enfermedades-neurologicas","status":"publish","type":"post","link":"https:\/\/neuropediatoolkit.org\/fr\/palivizumab-en-ninos-con-enfermedades-neurologicas\/","title":{"rendered":"Prophylaxie du VRS chez les enfants atteints de maladies neurologiques."},"content":{"rendered":"<p class=\"wp-block-paragraph\">La prophylaxie par le nirsevimab est recommand\u00e9e pour la pr\u00e9vention des maladies graves des voies respiratoires inf\u00e9rieures caus\u00e9es par le VRS, pendant les p\u00e9riodes de risque attendu d'infection par le VRS, dans\u00a0:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Patients de moins de 24 mois atteints de maladies neuromusculaires avec hypotonie marqu\u00e9e et\/ou faiblesse des muscles respiratoires. <\/li>\n\n\n\n<li>Patients de moins de 24 mois affect\u00e9s par l'\u00e9lectricit\u00e9 statique ou<br>maladies chromosomiques qui pr\u00e9sentent une hypotonie marqu\u00e9e (Ex : Prader Willi). <\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/nirsevimab-infov2-sep2025.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Int\u00e9gration de nirsevimab-infov2-sep2025.\"><\/object><a id=\"wp-block-file--media-22fd4c1b-a67d-477d-a8b2-c3d53671d872\" href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/nirsevimab-infov2-sep2025.pdf\">nirsevimab-infov2-sep2025<\/a><a href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/nirsevimab-infov2-sep2025.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-22fd4c1b-a67d-477d-a8b2-c3d53671d872\">D\u00e9charge<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/NirsevimabActualizacion.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Int\u00e9gration de NirsevimabUpdate.\"><\/object><a id=\"wp-block-file--media-05eb5b09-7881-4d43-ba5a-2addfb0966ca\" href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/NirsevimabActualizacion.pdf\">NirsevimabMise \u00e0 jour<\/a><a href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/NirsevimabActualizacion.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-05eb5b09-7881-4d43-ba5a-2addfb0966ca\">D\u00e9charge<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Int\u00e9gration de RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos.\"><\/object><a id=\"wp-block-file--media-53309992-92a1-4516-a3d2-9bbb5f918a81\" href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos.pdf\">RECOMMANDATIONS_SENEP_use_PALIVIZUMAB_corrected_by_AE_with_logos<\/a><a href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-53309992-92a1-4516-a3d2-9bbb5f918a81\">D\u00e9charge<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>La prophylaxie par le nirsevimab est recommand\u00e9e pour la pr\u00e9vention des maladies graves des voies respiratoires inf\u00e9rieures caus\u00e9es par le VRS, pendant les p\u00e9riodes de risque attendu d'infection par le VRS, dans\u00a0:<\/p>","protected":false},"author":1,"featured_media":2096,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-2092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aspectos-pediatricos","entry"],"_links":{"self":[{"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/posts\/2092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/comments?post=2092"}],"version-history":[{"count":4,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/posts\/2092\/revisions"}],"predecessor-version":[{"id":8507,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/posts\/2092\/revisions\/8507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/media\/2096"}],"wp:attachment":[{"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/media?parent=2092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/categories?post=2092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/tags?post=2092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}